Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei

References

• Annane, D., Sebille, V., Charpentier, C., Bollaert, P. E., Francois, B., Korach, J. M., Capellier, G., Cohen, Y., Azoulay, E., Troche, G., Chaumet-Riffaut, P. & Bellissant, E. (2002). Effect of treat-ment with low doses of hydrocortisone and fludro-cortisone on mortality in patients with septic shock. Journal of the American Medical Association, 288, 862-871.
   Google Scholar
• Anuntagool, N., Naigowit, P., Petkanchanapong, V., Aramsri, P., Panichakul, T. & Sirisinha, S. (2000). Monoclonal antibody-based rapid identification of Burkholcleria pseudomallei in blood culture fluid from patients with community-acquired septicaemia. Journal of Medical Microbiology, 49, 1075–1078.
   PubMed Web of Science ®Google Scholar
• Bagdade, J. D., Nielson, K. L. & Bulger, R. J. (1972). Reversible abnormalities in phagocytic function in poorly controlled diabetic patients. American Journal of the Medical Sciences, 263, 451-456.
   Google Scholar
• Bollaert, P. E., Charpentier, C., Levy, B., Debouverie, M., Audibert, G. & Larcan, A. (1998). Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Critical Care Medicine, 26, 645–650.
   PubMed Web of Science ®Google Scholar
• Briegel, J., Forst, H., Haller, M., Schelling, G., Kilger, E., Kuprat, G., Hemmer, B., Hummel, T., Lenhart, A., Heyduck, M., Stoll, C. & Peter, K. (1999). Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Critical Care Medicine, 27,723–732.
   PubMed Web of Science ®Google Scholar
• Brown, A. E., Dance, D. A., Suputtamongkol, Y., Chaowagul, W., Kongchareon, S., Webster, H. K. & White, N. J. (1991). Immune cell activation in melioidosis: increased serum levels of interferon-gamma and soluble interleukin-2 receptors without change in soluble CD8 protein. Journal of Infectious Diseases, 163, 1145–1148.
   PubMed Web of Science ®Google Scholar
• Calabrese, E. J. (1991). Principles of Animal Extrapolation. Chelsea, MI: Lewis.
   Google Scholar
• Chaowagul, W. (2000). Recent advances in the treatment of severe melioidosis. Acta Tropica, 74, 133–137.
   PubMed Web of Science ®Google Scholar
• Cheng, A. C. & Currie, B. J. (2005). Melioidosis: epidemiology, pathophysiology, and management. Clinical Microbiology Reviews, 18, 383–416.
   PubMed Web of Science ®Google Scholar
• Chierakul, W., Anunnatsiri, S., Short, J. M., Mahaijan, B., Mootsikapun, P., Simpson, A. J., Limmathurotsakul, D., Cheng, A. C., Stepniewska, K., Newton, P. N.,
   Google Scholar
• Chaowagul, W., White, N. J., Peacock, S. J., Day, N. P. & Chetchotisakd, P. (2005). Two randomized con-trolled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clinical Infectious Diseases, 41, 1105–1113.
   PubMed Web of Science ®Google Scholar
• Currie, B., Howard, D., Nguyen, V. T., Withnall, K. & Merianos, A. (1993). The 1990-1991 outbreak of melioidosis in the Northern Territory of Australia: clinical aspects. The Southeast Asian Journal of Tropical Medicine and Public Health, 24,436-443.
   Google Scholar
• Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R, Calandra, T., Dhainaut, J. F., Gerlach, H., Harvey, M., Marini, J. J., Marshall, J., Ranieri, M., Ramsay, G., Sevransky, J., Thompson, B. T., Townsend, S., Vender, J. S., Zimmerman, J. L. & Vincent, J. L. (2008). Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine, 36,296-327.
   Google Scholar
• Friedland, J. S., Suputtamongkol, Y., Remick, D. G., Chaowagul, W., Strieter, R. M., Kunkel, S. L., White, N. J. & Griffin, G. E. (1992). Prolonged elevation of interleukin-8 and interleukin-6 concen-trations in plasma and of leukocyte interleukin8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infection and Immunity, 60, 2402–2408.
   PubMed Web of Science ®Google Scholar
• Hoppe, I., Brenneke, B., Rohde, M., Kreft, A., Haussler, S., Reganzerowski, A. & Steinmetz, I. (1999). Characterization of a murine model of melioidosis: comparison of different strains of mice. Infection and Immunity, 67,2891–2900.
   PubMed Web of Science ®Google Scholar
• Hotchkiss, R. S. & Karl, I. E. (2003). The pathophy-siology and treatment of sepsis. New England Journal of Medicine, 348, 138–150.
   PubMed Web of Science ®Google Scholar
• Iwamoto, T., Kagawa, Y., Naito, Y., Kuzuhara, S. & Kojima, M. (2004). Steroid induced diabetes melli-tus and related risk factors in patients with neurologic diseases. Pharmacotherapy, 24,508–514.
   PubMed Web of Science ®Google Scholar
• Keh, D., Weber-Carstens, S. & Ahlers, O. (2008). Adjunctive therapies in severe sepsis and septic shock: current place of steroids. Current Infectious Disease Reports, 10, 354–61.
   PubMedGoogle Scholar
• Kumar, A., Short, J. & Parrillo, J. E. (1999). Genetic factors in septic shock. Journal of the American Medical Association, 282, 579–581.
   Web of Science ®Google Scholar
• Lauw, F. N., Simpson, A. J., Prins, J. M., Smith, M. D., Kurimoto, M., van Deventer, S. J., Speelman, P., Chaowagul, W., White, N. J. & van der Poll, T. (1999). Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines inter-leukin (IL)-18, IL-12, and IL-15 in severe melioidosis. Journal of Infectious Diseases, 180, 1878–1885.
   PubMed Web of Science ®Google Scholar
• Lauw, F. N., Simpson, A. J., Prins, J. M., van Deventer, S. J., Chaowagul, W., White, N. J. & van der Poll, T. (2000). The CXC chemokines gamma interferon (IFNgamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis. Infection and Immunity, 68, 3888–3893.
   PubMed Web of Science ®Google Scholar
• Li, Y., Cui, X., Li, X., Solomon, S. B., Danner, R. L., Banks, S. M., Fitz, Y., Annane, D., Natanson, C. & Eichacker, P. Q. (2008). Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Medicine, 34, 568–577.
   PubMed Web of Science ®Google Scholar
• Liu, H., Komai-Koma, M., Xu, D. & Liew, F. Y. (2006). Toll-like receptor 2 signaling modulates the functions of CD4 + CD25 + regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 7048-7053.
   Google Scholar
• Netea, M. G., van der Meer, J. W., van Deuren, M. & Kullberg, B. J. (2003). Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends in Immunology, 24, 254–258.
   PubMed Web of Science ®Google Scholar
• Prigent, H., Maxime, V. & Annane, D. (2004). Clinical review: corticotherapy in sepsis. Critical Care, 8, 122-129.
   PubMed Web of Science ®Google Scholar
• Santanirand, P., Harley, V. S., Dance, D. A., Raynes, J. G., Drasar, B. S. & Bancroft, G. J. (1997). Interferon-gamma mediates host resistance in a murine model of melioidosis. Biochemical Society Transactions, 25,287S.
   PubMed Web of Science ®Google Scholar
• Santanirand, P., Harley, V. S., Dance, D. A., Drasar, B. S. & Bancroft, G. J. (1999). Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infection and Immunity, 67,3593–3600.
   PubMed Web of Science ®Google Scholar
• Sirisinha, S., Anuntagool, N., Intachote, P., Wuthiekanun, V., Puthucheary, S. D., Vadivelu, J. & White, N. J. (1998). Antigenic differences between clinical and environmental isolates of Burkholderia pseudomallei. Microbiology and Immunology, 42, 731–737.
   PubMed Web of Science ®Google Scholar
• Suputtamongkol, Y., Kwiatkowski, D., Dance, D. A., Chaowagul, W. & White, N. J. (1992). Tumor necrosis factor in septicemic melioidosis. Journal of Infectious Diseases, 165, 561–564.
   PubMed Web of Science ®Google Scholar
• Suputtamongkol, Y., Chaowagul, W., Chetchotisakd, P., Lertpatanasuwun, N., Intaranongpai, S., Ruchutrakool,T.,Budhsarawong,D.,Mootsikapun, P., Wuthiekanun, V., Teerawatasook, N. & Lulitanond, A. (1999). Risk factors for melioidosis and bacteremic melioidosis. Clinical Infectious Diseases, 29, 408–413.
   PubMed Web of Science ®Google Scholar
• Titball, R W., Russell, P., Cuccui, J., Easton, A., Hague, A., Atkins, T., Sarkar-Tyson, M., Harley, V., Wren, B. & Bancroft, G. J. (2008). Burkholderia pseudomallei: animal models of infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 102 (Suppl. 1), S111-S116.
   Google Scholar
• Ulett, G. C., Hirst, R., Bowden, B., Powell, K. & Norton, R. (2003). A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. Journal of Antimicrobial Chemotherapy, 51,77-81.
   Google Scholar
• Utaisincharoen,P.,Tangthawornchaikul,N.,Kespichayawattana, W., Chaisuriya, P. & Sirisinha, S. (2001). Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiology and Immunology, 45,307–313.
   PubMed Web of Science ®Google Scholar
• White, N. J. (2003). Melioidosis. Lancet, 361, 1715–1722.
   PubMed Web of Science ®Google Scholar
• White, N. J., Dance, D. A., Chaowagul, W., Wattanagoon, Y., Wuthiekanun, V. & Pitakwatchara, N. (1989). Halving of mortality of severe melioidosis by ceftazidime. Lancet, ii, 697-701.
   Google Scholar
• Wiersinga, W. J., Dessing, M. C., Kager, P. A., Cheng, A. C., Limmathurotsakul, D., Day, N. P., Dondorp, A. M., van der Poll, T. & Peacock, S. J. (2007a). High throughput mRNA profiling characterizes the expression of inflammatory molecules in sepsis caused by Burkholderia pseudomallei (melioidosis). Infection and Immunity, 75,3074–3079.
   PubMed Web of Science ®Google Scholar
• Wiersinga, W. J., Wieland, C. W., Dessing, M. C., Chantratita, N., Cheng, A. C., Limmathurotsakul, D., Chierakul, W., Leendertse, M., Florquin, S., de Vos, A. F., White, N., Dondorp, A. M., Day, N. P., Peacock, S. J. & van der Poll, T. (2007b). Toll-like receptor 2 impairs host defense in Gram-negative sepsis caused by Burkholderia pseudomallei (melioido-sis). PLoS Medicine, 4, e248.
   PubMed Web of Science ®Google Scholar
• Woods, D. E., Jones, A. L. &Hill, P. J. (1993). Interaction of insulin with Pseudomonas pseudomallei. Infection and Immunity, 61, 4045–4050.
   PubMed Web of Science ®Google Scholar
• Wuthiekanun, V., Smith, M. D., Dance, D. A., Walsh, A. L., Pitt, T. L. & White, N. J. (1996). Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. Journal of Medical Microbiology, 45,408-412.
   Google Scholar
• Yamashiro, S., Kawakami, K., Uezu, K., Kinjo, T., Miyagi, K., Nakamura, K. & Saito, A. (2005). Lower expression of Thl-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clinical Experimental Immunology, 139, 57–64.
   PubMed Web of Science ®Google Scholar
• Zanotti, S. & Kumar, A. (2002). Cytokine modulation in sepsis and septic shock. Expert Opinion on Investigational Drugs, 11, 1061–1075.
   PubMed Web of Science ®Google Scholar